Business Wire India
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
- Launch of Her Promise ESG platform creates a framework by which Organon aims to advance innovation and progress in women’s health and contribute to UN Sustainable Development Goals
- Through the Her Promise Access Initiative, Organon’s goal is to provide 100 million girls and women in low- and middle-income countries with affordable access to contraceptive options by 2030
- Funding to global NGO Women Deliver for their Young Leaders Program and other advocacy work, including support for young people around the world to advocate for and advance women’s health and gender equality
Organon (NYSE: OGN), a global women’s healthcare company, today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG Report introduces Organon’s ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of the ESG Report and launch of Her Promise coincides with Organon’s one year anniversary and reflects the company’s vision to create a better and healthier every day for every woman around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005205/en/
Organon Her Promise Mural found at Organon global headquarters in Jersey City, New Jersey. Created by local Japanese American artist Riiisa Boogie who crafts detailed imaginary through textile, nature, portraits, flowing abstractions and uniquely creative characters. (Photo: Organon)
As the only global women’s health company of its kind, Organon is well positioned to help address several current and growing women’s health challenges. For example, nearly half of all pregnancies worldwide – about 121 million in total – are unintended. According to a 2019 study, an estimated 218 million women and girls (ages 15-49) in low-and-middle income countries had an unmet need for modern contraception. Through Her Promise, Organon is making focused investments and forming strategic partnerships with the goal of introducing and expanding access to health solutions that improve women’s health and advance gender equity, inside and outside Organon.
“In just one year, Organon has made considerable progress in addressing gender-related disparities in health by listening to women and investing in areas where high unmet needs exist. Since our launch, we have focused on treatment gaps that need to be addressed, like unintended pregnancy, fertility, post-partum hemorrhage, pre-term labor, endometriosis, and bacterial vaginosis, and will continue to strive to deliver innovation, improve access and expand choice for women,” says Kevin Ali, Organon’s Chief Executive Officer. “The goals stated in our first ESG Report create a roadmap for the future of how we will continue to propel forward and partner to transform the current women’s health environment.”
On its one-year anniversary, Organon is making the following goals to achieve Her Promise:
- To improve access to low-cost contraceptive options in 69 of the world’s least developed countries. Through the OrganonHer Promise Access Initiative, Organon is working with global organizations to provide family planning information, education and access to low-cost contraceptive options. Organon’s goal is to provide 100 million girls and women in low- and middle- income countries with affordable access to contraceptive options by 2030.
- To redefine and harness innovation in women’s health. Organon will dedicate a majority of its pre-clinical and clinical development activity toward the unmet health needs of women. Organon has already begun with development activities in high unmet need areas including postpartum hemorrhage, endometriosis, and pre-term labor.
- Expand access to treatment options that improve her health and help secure her promise. Working together with global organizations, Organon plans to expand access to treatment options for post-partum hemorrhage in women, in both developed and developing markets. We will also seek to help address affordability of fertility treatments and access to education to decrease the unmet medical need in fertility.
- Aim to achieve balanced gender representation through all levels of Organon globally by 2030 and pay equity. Organon has had a strong start by launching with a Board of Directors that consists of accomplished individuals with exceptional skills and expertise, and also represents gender and racial diversity. Currently, Organon’s Board is the most diverse healthcare board on the S&P 500.
- Aim to support the transition to a low carbon economy, with an ambition to achieve net zero greenhouse gas emissions. We also aim to integrate water stewardship and circular economy principles into our business models. The report details concrete short- and mid-term actions we will take to meet these long-term ambitions.
- Uphold the highest levels of ethics and integrity throughout its business.
In addition, as part of its commitment to advancing gender equity through Her Promise, Organon has provided US $1.4M to Women Deliver to fund its Young Leaders Program and other advocacy work, as well as support the Women Deliver 2023 Conference (WD2023). The funding will help Young Leaders across the world to achieve their advocacy goals in gender equality and health through financial resources, mentorship, and technical assistance.
“The Board is committed to achieving both Organon’s business goals as well as contributing to societal goals, and to continuing to drive the company’s ESG strategy,” says Carrie Cox, Board Chairman. “We are pleased to be in a position to publish a comprehensive ESG report just one year after the company’s establishment as a standalone company and highlight our purpose and goals in improving the health of women and girls.”
The Board’s governance committee, called the ESG Committee, is comprised of five members and chaired by pharmaceutical industry veteran Robert Essner, all of whom bring considerable expertise from across a variety of disciplines.
For more details on Organon’s ESG strategy, priorities, and initiatives, download the full 2021 ESG Report at https://www.organon.com/about-organon/environmental-social-governance/.
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.
Forward-Looking Statement of Organon
Organon makes various statements in this press release, including, but not limited to, statements about management’s expectations about Organon’s environmental, social, and governance strategy and goals. These “forward-looking statements” may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).
The content is by Business Wire India. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.